 |
66 Companies | 59 Products |
|
|
59 Products | |
344 Diseases | |
313 Trials |  |
11771 News |  |
| «12345678910111213...220221» |
- elraglusib (9-ING-41) / Actuate Therap
Investigating the Role of Tuftelin 1 in Mesothelial Mesenchymal Transition and Pleural Fibrosis (San Diego Convention Center, Area E (Hall A-B2, Ground Level)) - Feb 20, 2024 - Abstract #ATS2024ATS_2070;
inhibitor 9-ING-41... These studies strongly support the further study and therapeutic targeting of Tuft1 and related signaling for the treatment of PF.
- | LY294002 / Eli Lilly
Journal: Targeting scleral remodeling and myopia development in form deprivation myopia through inhibition of EFEMP1 expression. (Pubmed Central) - Feb 20, 2024
Validation was performed using lentivirus-induced overexpression and shRNA targeting EFEMP1 in combination with LY294002, a PI3K inhibitor...In contrast, the AAV-mediated overexpression of EFEMP1 exacerbated the development of myopia and resulted in further thinning of collagen fibers in the posterior sclera. In summary, adjusting EFEMP1 concentrations could potentially serve as a viable approach to prevent and treat myopia by influencing the remodeling process of the posterior sclera.
- || RLY-5836 / Relay Therap
Enrollment closed, Trial completion date, Trial primary completion date, Combination therapy, Metastases: First-in-Human Study of RLY-5836 in Advanced Breast Cancer and Other Solid Tumors (clinicaltrials.gov) - Feb 20, 2024
P1, N=265, Active, not recruiting, Sponsor: Relay Therapeutics, Inc.
In summary, adjusting EFEMP1 concentrations could potentially serve as a viable approach to prevent and treat myopia by influencing the remodeling process of the posterior sclera. Recruiting --> Active, not recruiting | Trial completion date: Jan 2026 --> Jul 2024 | Trial primary completion date: Dec 2025 --> Jun 2024
- | fexofenadine / Generic mfg.
Journal: Fexofenadine-loaded chitosan coated solid lipid nanoparticles (SLNs): A potential oral therapy for ulcerative colitis. (Pubmed Central) - Feb 19, 2024
The ameliorative potential of FEX-CS-SLNs outperformed that of FEX-pure and FEX-market. The exceptional protective effect of FEX-CS-SLNs makes it a potentially effective oral system for managing ulcerative colitis.
- | LY294002 / Eli Lilly, picropodophyllin (AXL1717) / Axelar
Preclinical, Journal: Suppression of overactive IGF-1 attenuates trauma-induced heterotopic ossification in mice. (Pubmed Central) - Feb 19, 2024
Inhibitors of PI3K (LY294002) and mTOR (Rapamycin) both suppressed the IGF-1-stimulated mTOR signal and mitigated the formation of ectopic bones significantly. In conclusion, our results indicated that IGF-1 mediated the progression of traumatic HO through PI3K/Akt/mTOR signaling, and suppressing IGF-1 signaling cascades attenuated HO formation, providing a promising therapeutic strategy targeting HO.
- Accelerated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Clinicopathologic Features and Survival Characteristics in the Era of Novel Therapies (Exhibit Hall; Poster Board Number: 297) - Feb 18, 2024 - Abstract #USCAP2024USCAP_1140;
A-CLL is a distinct clinicopathologic subtype of CLL/SLL characterized by a higher frequency of B-symptoms and cytopenias, elevated LDH, and a higher prevalence of trisomy 12 and TP53 deletion. The histologic criteria for A-CLL as defined by Gin
- Accelerated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Clinicopathologic Features and Survival Characteristics in the Era of Novel Therapies (BCC Room 339) - Feb 18, 2024 - Abstract #USCAP2024USCAP_904;
A-CLL is a distinct clinicopathologic subtype of CLL/SLL characterized by a higher frequency of B-symptoms and cytopenias, elevated LDH, and a higher prevalence of trisomy 12 and TP53 deletion. The histologic criteria for A-CLL as defined by Gin
- | Journal: Metabolic rewiring and autophagy inhibition correct lysosomal storage disease in mucopolysaccharidosis IIIB. (Pubmed Central) - Feb 16, 2024
Indeed, metabolomic analyses revealed defects of mitochondrial activity accompanied by anaerobic metabolism and inhibition of AMP-activated protein kinase (AMPK), which acts on metabolism and autophagy, rescues lysosomal defects. These results provide insights into the molecular mechanisms of MPS IIIB physiopathology, supporting the development of new promising approaches based on autophagy inhibition and metabolic rewiring to correct lysosomal pathology in MPSs.
- || parsaclisib (INCB50465) / Incyte
P2 data, Journal: A phase 2 study of the PI3K? inhibitor parsaclisib in relapsed and refractory marginal zone lymphoma (CITADEL-204). (Pubmed Central) - Feb 16, 2024
P2
TEAEs led to dose interruptions, reductions, and discontinuations in 56.0%, 16.0%, and 29.0% of all patients, respectively. Durable responses and overall manageable safety profile were demonstrated in patients with R/R MZL treated with parsaclisib monotherapy.
- | parsaclisib (INCB50465) / Incyte
Trial completion date: A Study of INCB050465 in Subjects With Relapsed or Refractory Marginal Zone Lymphoma (CITADEL-204) (clinicaltrials.gov) - Feb 15, 2024
P2, N=110, Active, not recruiting, Sponsor: Incyte Corporation
Durable responses and overall manageable safety profile were demonstrated in patients with R/R MZL treated with parsaclisib monotherapy. Trial completion date: Dec 2023 --> May 2024
- | ispinesib (SB-715992) / Cytokinetics, Zydelig (idelalisib) / Gilead
Preclinical, Journal, IO biomarker: Design, synthesis, molecular docking, and in vitro studies of 2-mercaptoquinazolin-4(3H)-ones as potential anti-breast cancer agents. (Pubmed Central) - Feb 15, 2024
The relative gene expression of pro-apoptotic and anti-apoptotic genes revealed an overexpression of the P53 and BAX genes and a downregulation of the BCL-2 gene by real-time PCR. So, this work proved that compounds 3a, 3b, and 3e could be developed as anticancer candidates, via their P53-dependent apoptotic activity.
- | Imbruvica (ibrutinib) / AbbVie, J&J
Preclinical, Journal: Ibrutinib-induced pulmonary angiotensin-converting enzyme activation promotes atrial fibrillation in rats. (Pubmed Central) - Feb 15, 2024
Importantly, we observed that perindopril significantly mitigated ibrutinib-induced left atrial remodeling and AF promotion by inhibiting the activation of the ACE and its downstream CSK-Src signaling pathway. These findings indicate that the Ibrutinib-induced activation of the ACE contributes to AF development and could serve as a novel target for potential prevention strategies.
- parsaclisib (INCB50465) / Incyte
TARGETING PI3KDELTA FUNCTION FOR TREATMENT OF CHRONIC GRAFT?VERSUS?HOST DISEASE (Hall 2) - Feb 14, 2024 - Abstract #EBMT2024EBMT_2612;
These data provide the scientific rationale for PI3K? inhibition as a therapeutic approach for patients with cGVHD
- | Journal: The Potential of PIP3 in Enhancing Wound Healing. (Pubmed Central) - Feb 14, 2024
Free PIP3 and the Q-starch/PIP3 complexes inherently activated the AKT signaling pathway, which is responsible for crucial wound healing processes such as migration; this was also observed in wound assays in mice. PIP3 was identified as a promising molecule for enhancing wound healing, and its ability to circumvent PI3K inhibition suggests possible implications for chronic wound healing.
- | LY294002 / Eli Lilly
Journal: Development of certain benzylidene coumarin derivatives as anti-prostate cancer agents targeting EGFR and PI3K? kinases. (Pubmed Central) - Feb 13, 2024
PIP3 was identified as a promising molecule for enhancing wound healing, and its ability to circumvent PI3K inhibition suggests possible implications for chronic wound healing. Compound 4c displayed cytotoxicity more than erlotinib in the MDA-MB-231 cells with IC50 8.5
- | Journal: Antiplatelet effects of the CEACAM1-derived peptide QDTT. (Pubmed Central) - Feb 12, 2024
QDTT also suppressed platelet secretion and "inside-out" GP IIb/IIIa activation by convulxin, along with inhibiting PI3K/Akt pathways. QDTT curtailed FeCl3-induced mesenteric thrombosis without significantly prolonging bleeding time, implying the potential of CEACAM1 A1 domain against platelet activation without raising bleeding risk, thus paving the way for novel antiplatelet drugs.
- | Journal: The Neuroprotective Effects of BMSC-Derived Exosomes against Glutamate-Induced HT22 Cell Cytotoxicity. (Pubmed Central) - Feb 12, 2024
The protective effect of BMSC-Exos was weakened when PI3K/Akt inhibitor and mTOR inhibitor were added. To sum up, we draw the following BMSC-Exos can reduce neuronal apoptosis and apoptosis-related protein expression after glutamate stimulation by regulating the PI3K/Akt/mTOR signaling pathway.
- || Venclexta (venetoclax) / Roche, AbbVie, Imbruvica (ibrutinib) / AbbVie, J&J
Review, Journal: Treatment of Double-Refractory Chronic Lymphocytic Leukemia-An Unmet Clinical Need. (Pubmed Central) - Feb 10, 2024
This review explores the resistance mechanisms for both ibrutinib and venetoclax. Moreover, we present innovative approaches evaluated for treating double-refractory CLL.
- | paclitaxel / Generic mfg.
Journal, Combination therapy: GBP2 enhances paclitaxel sensitivity in triple?negative breast cancer by promoting autophagy in combination with ATG2 and inhibiting the PI3K/AKT/mTOR pathway. (Pubmed Central) - Feb 9, 2024
It functions as a critical regulator of activated autophagy by co?acting with ATG2 and inhibiting the PI3K/AKT/mTOR pathway, which contributes to increasing sensitivity of TNBC cells to PTX. Therefore, GBP2 is a promising therapeutic target for enhancing TNBC treatment.
- | Piqray (alpelisib) / Novartis, RLY-2608 / Relay Therap
Journal: Allosteric PI3K-alpha inhibition overcomes on-target resistance to orthosteric inhibitors mediated by secondary PIK3CA mutations. (Pubmed Central) - Feb 9, 2024
PIK3CA mutations occur in ?8% of cancers, including ?40% of HR-positive breast cancers, where the PI3K-alpha (PI3K?)-selective inhibitor alpelisib is FDA approved in combination with fulvestrant...Some mutations had differential effects on PI3K?-selective versus pan-PI3K inhibitors, but resistance induced by all mutations could be overcome by the novel allosteric pan-mutant-selective PI3K?-inhibitor RLY-2608...Some mutations had differential effects on PI3Ka-selective vs. pan-PI3K inhibitors, but resistance induced by all mutations could be overcome by the novel allosteric pan-mutant-selective PI3Ka-inhibitor RLY-2608. Together, these findings provide insights to guide strategies to overcome resistance in PIK3CA-mutated cancers.
- | LY294002 / Eli Lilly
Journal: Inhibition of PI3K/AKT signaling pathway prevents blood-induced heterotopic ossification of the injured tendon. (Pubmed Central) - Feb 8, 2024
At last, the small molecule drug PI3K inhibitor LY294002 was used for in vivo and in vitro HO treatment...Our findings indicate that the upregulated PI3K/AKT signaling pathway is implicated in the aggravation of tendon HO. Therefore, inhibitors targeting the PI3K/AKT pathway would be a promising approach to treat blood-induced tendon HO.
- || Review, Journal: Therapeutic evolution in HR+/HER2- breast cancer: from targeted therapy to endocrine therapy. (Pubmed Central) - Feb 8, 2024
The mechanisms of action of various drugs, including targeted therapy drugs and endocrine hormone therapy drugs, and their potential synergistic effects are deeply discussed. In addition, clinical trials of these drugs that have been completed or are still in progress are included.
- || Review, Journal, Tumor mutational burden, PD(L)-1 Biomarker, IO biomarker, Synthetic lethality: Therapeutic Role of Synthetic Lethality in ARID1A-Deficient Malignancies. (Pubmed Central) - Feb 8, 2024
As ARID1A deficiency correlates with enhanced tumor mutability, microsatellite instability, high tumor mutation burden, increased programmed death-ligand 1 expression, and T-lymphocyte infiltration, ARID1A-deficient cells can be a potential therapeutic target for immune checkpoint inhibitors that warrants further exploration. In this review, we discuss the role of ARID1A in carcinogenesis, its crosstalk with other signaling pathways, and strategies to make ARID1A-deficient cells a potential therapeutic target for patients with cancer.
- | Journal: ?1 integrin mediates unresponsiveness to PI3K? inhibition for radiochemosensitization of 3D HNSCC models. (Pubmed Central) - Feb 8, 2024
Finally, we demonstrate that targeting of the cell adhesion molecule ?1 integrin on top of Alpelisib sensitizes non-responders to radiochemotherapy. Taken together, our study demonstrates the sensitizing potential of Alpelisib and other PI3K inhibitors in HNSCC models and uncovers a novel ?1 integrin-dependent mechanism that may prove useful in overcoming resistance to PI3K inhibitors.
- | Journal: Sakuranetin reduces inflammation and chondrocyte dysfunction in osteoarthritis by inhibiting the PI3K/AKT/NF-?B pathway. (Pubmed Central) - Feb 8, 2024
In vivo, SK treatment effectively alleviated the degeneration of cartilage and subchondral bone, thereby delaying the progression of OA. In summary, SK alleviates chondrocyte inflammation and promotes chondrogenesis by inhibiting the PI3K/AKT/NF-?B pathway, thereby improving OA progression.
- | Preclinical, Journal: Application of bacteriophage ?PaP11-13 attenuates rat Cutibacterium acnes infection lesions by promoting keratinocytes apoptosis via inhibiting PI3K/Akt pathway. (Pubmed Central) - Feb 8, 2024
However, the regulation of this cell cycle has not been proven to be directly mediated by phages. The hint of ternary relation among "phage-bacteria-host" inspires huge interest in future phage therapy studies.
- | Elaspol (sivelestat) / Ono Pharma
Journal, IO biomarker: Sivelestat ameliorates sepsis-induced myocardial dysfunction by activating the PI3K/AKT/mTOR signaling pathway. (Pubmed Central) - Feb 8, 2024
The protective effect of sivelestat against SIMD was reversed by the PI3K inhibitor LY294002. In summary, sivelestat can protect against SIMD by activating the PI3K/AKT/mTOR signaling pathway.
- | LY294002 / Eli Lilly
Journal: Arsenic-induced IGF-1 signaling impairment and neurite shortening: The protective roles of IGF-1 through the PI3K/Akt axis. (Pubmed Central) - Feb 8, 2024
Inhibition of PI3K/Akt by LY294002 diminished the protective effects of IGF-1 against sodium arsenite-induced neurite retraction. Together, our findings suggested that sodium arsenite-impaired IGF-1 signaling, leading to neurite shortening through IGF-1/PI3K/Akt.
- | Piqray (alpelisib) / Novartis, Zydelig (idelalisib) / Gilead
Preclinical, Journal, Liquid biopsy, Biopsy: Integrating cfDNA liquid biopsy and organoid-based drug screening reveals PI3K signaling as a promising therapeutic target in colorectal cancer. (Pubmed Central) - Feb 8, 2024
Liquid biopsy holds significant promise for improving precision treatment and tumor prognosis in colorectal cancer patients. The combination of biomarker-based drug prediction with organoid-based functional drug sensitivity assay may lead to more effective cancer treatment.
- | LY294002 / Eli Lilly
Journal: Downregulating ANGPTL3 by miR-144-3p promoted TGF-?1-induced renal interstitial fibrosis via activating PI3K/AKT signaling pathway. (Pubmed Central) - Feb 7, 2024
Under comparable conditions, the use of LY294002, an inhibitor of the PI3K/AKT pathway, nullified the effects caused by the knockdown of ANGPTL3. Collectively, these findings indicate that miR-144-3p exacerbates RIF through PI3K/AKT pathway activation by targeting ANGPTL3, highlighting a novel potential therapeutic target for RIF management.
- | Journal: Mechanosensitive channel of large conductance enhances the mechanical stretching-induced upregulation of glycolysis and oxidative metabolism in Schwann cells. (Pubmed Central) - Feb 6, 2024
Collectively, these findings indicate that miR-144-3p exacerbates RIF through PI3K/AKT pathway activation by targeting ANGPTL3, highlighting a novel potential therapeutic target for RIF management. Mechanical stretching activates MscL-G22S to significantly promote the energy metabolism of SCs and the production of energic substrates, which may be applied to enhance nerve regeneration via the glia-axonal metabolic coupling.
- | Journal, PARP Biomarker: Use of antioxidant nanoliposomes for co-delivery of PTEN plasmids and plumbagin to induce apoptosis in hepatic cancer cells. (Pubmed Central) - Feb 6, 2024
Other cellular events such as Caspase-7 overexpression and PI3K, AKT, PARP, and mTOR inhibition led to the apoptosis in hepatic cancer cells. The mRNA expression profile of PTEN, PI3K, AKT3, caspase-7, PARP and mTOR proteins, primarily controlling the cancer cell proliferation and apoptosis, suggest that exogenous supply of PTEN could regulate the expression of oncogenic proteins and thus cancer progression.
- | LY294002 / Eli Lilly
Journal: Myricetin induces M2 macrophage polarization to alleviate renal tubulointerstitial fibrosis in diabetic nephropathy via PI3K/Akt pathway. (Pubmed Central) - Feb 5, 2024
The mRNA expression profile of PTEN, PI3K, AKT3, caspase-7, PARP and mTOR proteins, primarily controlling the cancer cell proliferation and apoptosis, suggest that exogenous supply of PTEN could regulate the expression of oncogenic proteins and thus cancer progression. This study demonstrated that myricetin effectively mitigates kidney injury in DN mice through the regulation of macrophage polarization via the PI3K/Akt signaling pathway.
- | PF-04691502 / Pfizer
Journal: Inhibitor PF-04691502 works as a senolytic to regulate cellular senescence. (Pubmed Central) - Feb 5, 2024
These results suggest that PF-04691502 holds promise as a new senolytic drug. This paper provides important insights into the potential application of PF-04691502 in the study of cell senescence.
- Zejula (niraparib) / GSK, J&J, Aliqopa (copanlisib) / Bayer
COPANIRA: Phase Ib trial of copanlisib (PI3K inhibitor) and niraparib (PARP inhibitor) in recurrent ovarian and endometrial cancer () - Feb 3, 2024 - Abstract #SGO2024SGO_569;
P1
Although clinical benefit was achieved in a moderate proportion of patients, the ORR was low. Assessment of molecular correlates of response and resistance is ongoing.
- Clarifying intratumoral heterogeneity in ovarian cancer via transcriptomic analysis of the PI3K/AKT/mTOR pathway () - Feb 3, 2024 - Abstract #SGO2024SGO_534;
Our study proposed a machine learning-based model, which was capable of predicting the prognosis and TME score of OC patients. Our findings provide valuable insights into the molecular mechanisms driving OV and pave the way for the development of novel diagnostic and therapeutic strategies targeting the PI3K/AKT/mTOR pathway.
- Enhertu (fam-trastuzumab deruxtecan-nxki) / Daiichi Sankyo, AstraZeneca
Exploring the mechanisms of resistance to trastuzumab-deruxtecan in endometrial cancer cells () - Feb 3, 2024 - Abstract #SGO2024SGO_451;
However, no synergistic cell death was observed when T-DXd was combined with alpelisib. When treated with T-DXd, there was no clear evidence that the PI3K/AKT pathway was directly affected.
- LCI139: In silico design of a novel multitarget small molecular inhibitor for the treatment of PTEN-mutant endometrial adenocarcinoma () - Feb 3, 2024 - Abstract #SGO2024SGO_440;
Importantly, we show that LCI139 potency correlates to PTEN mutational status and LCI139 displays decreased toxicity compared to single agent reference compounds. Preliminary data and the literature support a mechanism by which PTEN loss could encode increased sensitivity to CDK9 inhibition.
- | fluoxetine / Generic mfg.
Journal: Fluoxetine exerts anti-inflammatory effects on human epidermal keratinocytes and suppresses their endothelin release. (Pubmed Central) - Feb 2, 2024
Collectively, our findings demonstrate that fluoxetine exerts potent anti-inflammatory effects, and suppresses the release of the endogenous itch mediator endothelins in human keratinocytes, most likely via interfering with the PI3K pathway. Thus, clinical studies are encouraged to explore whether the currently reported beneficial effects translate in
- | LY294002 / Eli Lilly
Journal: Leptin promotes proliferation of human undifferentiated spermatogonia by activating the PI3K/AKT/mTOR pathway. (Pubmed Central) - Feb 2, 2024
Thus, clinical studies are encouraged to explore whether the currently reported beneficial effects translate in A certain concentration of leptin (25?100
- || Adcetris (brentuximab vedotin) / Takeda, Pfizer
Review, Journal: Aggressive T-cell lymphomas: 2024: Updates on diagnosis, risk stratification, and management. (Pubmed Central) - Feb 2, 2024
This includes the CD30 directed antibody drug conjugate brentuximab vedotin...The use of checkpoint inhibitors in the treatment of PTCL is still controversial, with best results seen in cases of extranodal natural killer cell/T-cell lymphoma. Bispecific antibody-based treatments and chimeric antigen receptor cell-based therapies are in clinical trials.
- | perifosine (D21266) / AEterna Zentaris, MG132 / Jilin University, Dorothy M. Davis Heart and Lung Research Institute, SP600125 / BMS
Journal: Study on the mechanism of CXCL12/CXCR4-axis-mediated upregulation of IL-8 and IL-6 on the biological function of acute T lymphocyte leukaemia cells. (Pubmed Central) - Feb 2, 2024
Bispecific antibody-based treatments and chimeric antigen receptor cell-based therapies are in clinical trials. Treatment of cells with AMD3100, a CXCR4 antagonist, and G-CSF blocked the CXCL12/CXCR4 axis, inducing biological changes in the leukaemia cells and altering IL-8 and IL-6 levels...ELISA results confirmed that MG-132 (10
- | Journal: MicroRNA profile of extracellular vesicles released by M (Pubmed Central) - Feb 2, 2024
Treatment of cells with AMD3100, a CXCR4 antagonist, and G-CSF blocked the CXCL12/CXCR4 axis, inducing biological changes in the leukaemia cells and altering IL-8 and IL-6 levels...ELISA results confirmed that MG-132 (10 The results suggest that the release by M
- | Zarnestra (tipifarnib) / Kura Oncology
Journal: Evolutionary dynamics of tipifarnib in HRAS mutated head and neck squamous cell carcinoma. (Pubmed Central) - Feb 2, 2024
Our case study highlights the potential of targeting HRAS mutations with tipifarnib in R/M HNSCC and identifies potential mechanisms of acquired resistance to tipifarnib, along with immuno-, chemo-, and radiation therapy. Preclinical results provide a firm foundation for further investigation of drug combinations of HRAS-and PI3K -targeting therapeutics in R/M HRAS-driven HNSCC.
- | Lunsumio (mosunetuzumab) / Roche, Biogen
Journal: Indirect Treatment Comparisons of Mosunetuzumab With Third- and Later-Line Treatments for Relapsed/Refractory Follicular Lymphoma. (Pubmed Central) - Feb 2, 2024
P1/2
Although preliminary results somewhat favored CART therapies, limitations and uncertainties remain because of intrinsic differences in study design. Mosunetuzumab could thus be a promising treatment option for patients with RR FL after ?2 prior therapies.
- || Copiktra (duvelisib) / Secura Bio, Yakult Honsha
Clinical, P1 data, Journal: Japanese phase Ib study of the oral PI3K-? and -? inhibitor duvelisib in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma. (Pubmed Central) - Feb 1, 2024
The most common grade???3 adverse events were neutropenia (50%), anemia (30%) and thrombocytopenia (20%). Duvelisib 25
- | MK-2206 / Merck (MSD), LY294002 / Eli Lilly
Journal: Qihuang Zhuyu formula alleviates coronary microthrombosis by inhibiting PI3K/Akt/?IIb?3-mediated platelet activation. (Pubmed Central) - Jan 31, 2024
QHZYF interferes with coronary microthrombosis through inhibition of platelet adhesion, activation and inflammatory crosstalk, thus has potential in clinical anti-platelet applications. Calyson, Oroxin A, Protosappanin A, Kaempferol and Geniposide may be the major active ingredient groups of QHZYF that alleviate coronary microthrombosis.
- | Journal: Fecal Microbiota Transplantation Alleviates Allergic Rhinitis via CD4 T Cell Modulation Through Gut Microbiota Restoration. (Pubmed Central) - Jan 31, 2024
Disturbed gut microbiota causes an altered immune-inflammatory state in mice and increases susceptibility to AR. This study suggested the regulatory role of the gut-nose axis in the pathogenesis of AR is an emerging field, which provides novel directions and ideas for the treatment of AR.
- | Journal: METTL3-mediated m6A modification of EPPK1 to promote the development of esophageal cancer through regulating the PI3K/AKT pathway. (Pubmed Central) - Jan 31, 2024
In addition, METTL3 deficiency reduced EPPK1 expression to inactivate the PI3K/AKT pathway. Our results revealed that METTL3 deficiency regulated the m6A modification of EPPK1 to inhibit the PI3K/AKT pathway, thereby restraining the progression of esophageal cancer.
- | Preclinical, Journal: Self-assembled redox-responsive BRD4 siRNA nanoparticles: fomulation and its in (Pubmed Central) - Jan 31, 2024
This might be related with the silence of BRD4, then inhibition of PI3K/Akt and c-Myc. Our results demonstrate that L-NPs/siBRD4 are a novel delivery system with anticancer, which may provide a more effective strategy for GC treatment.